
Feb 23 (Reuters) - Astellas Pharma Inc 4503.T:
ASTELLAS PHARMA: CO & VIR BIOTECHNOLOGY ENTERED GLOBAL STRATEGIC COLLABORATION TO ADVANCE VIR-5500 FOR TREATMENT OF PROSTATE CANCER
ASTELLAS: CO WILL OBTAIN EXCLUSIVE RIGHTS TO COMMERCIALIZE VIR-5500 EXCLUDING-U.S.
ASTELLAS: TO LEAD COMMERCIALIZATION OF VIR-5500 IN THE U.S. WITH VIR BIOTECHNOLOGY RETAINING OPTION TO CO-PROMOTE
ASTELLAS: VIR BIOTECHNOLOGY TO GET $335 MILLION IN UPFRONT & NEAR-TERM MILESTONE PAYMENTS, WILL SPLIT U.S. PROFIT/LOSS EQUALLY WITH ASTELLAS
ASTELLAS: ELIGIBLE TO RECEIVE UP TO ADDITIONAL $1.37 BILLION IN DEVELOPMENT, REGULATORY & SALES MILESTONES
ASTELLAS: UNDER TERMS OF VIR BIOTECHNOLOGY'S LICENSING DEAL WITH SANOFI, A PORTION OF CERTAIN COLLABORATION PROCEEDS WILL BE SHARED WITH SANOFI